Isoform selective PI3 kinase inhibitors for cancer, thrombosis and inflammatory disease

用于癌症、血栓形成和炎症性疾病的异构体选择性 PI3 激酶抑制剂

• 批准号: nhmrc : 1093062
• 负责人: Prof Philip Thompson
• 金额: $ 31.64万
• 依托单位: Monash University
• 依托单位国家: 澳大利亚
• 项目类别: Development Grants
• 财政年份: 2015
• 资助国家: 澳大利亚
• 起止时间: 2015-01-01 至 2016-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/isoform-selective-pi3-inflammatory-disease/519406
• 关键词: Isoform; selective; PI3; kinase; inhibitors

Inhibitors of the PI3 kinase family of enzymes have potential as therapeutics in diseases such as cancer, thrombosis and inflammatory disease. In this project the investigators will develop a new class of PI3 kinase inhibitors they have discovered, optimizing their pharmaceutical properties and evaluating them in models of disease. The aim is to develop a candidate for human clinical studies.

酶的PI3激酶家族的抑制剂具有作为疾病如癌症、血栓形成和炎性疾病的治疗剂的潜力。在该项目中，研究人员将开发他们发现的一类新的PI3激酶抑制剂，优化其药物特性并在疾病模型中对其进行评估。其目的是为人类临床研究开发一种候选药物。